Clinical trials: Aortic Valve Disease
Aortic Stenosis
Medtronic CoreValve Evolut R U.S. Clinical Study
The study objectives are to assess the safety and efficacy of the CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis are considered at high or extreme risk…
- Trial name
- NCT02207569
- Testing
- CoreValve Evolut R TAVR system
- Where
- 23 sites in United States
- Volunteers
- 241 people
- Sponsor
- Medtronic Cardiovascular
Aortic Valve Stenosis
VitaFlow™ Transcatheter Aortic Valve System Pre-market Trial
This is a pre-market clinical investigation aiming to evaluate the safety and effectiveness of MicroPort™ CardioFlow VitaFlow™ Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.
- Trial name
- NCT04655742
- Testing
- VitaFlow™ Transcatheter Aortic Valve System
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Valvular Heart Disease, Aortic Arch Aneurysm
The Effects of Intermittent Hypoxic-hyperoxic Preconditioning for Patients Undergoing Cardiopulmonary Bypass.
The aim of the study is to evaluate the effects of intermittent hypoxic-hyperoxic training (IHHT) to protect myocardium against perioperative myocardial injury during cardiac surgery using cardiopulmonary bypass.
- Conditions
- Valvular Heart Disease, Aortic Arch Aneurysm, Surgery
- Trial name
- NCT04833283
- Testing
- ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT), ReOxy Cardio device
- Where
- Russia
- Volunteers
- 115 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Aortic Valve Disease, Mitral Valve Disease
The Study on the Use of "UniLine" Bioprosthesis in the Treatment of Isolated Aortic and Mitral Valve Diseases
The goal of this open, prospective, multicenter study is analyze long-term outcomes of aortic/mitral valve replacement using the "UniLine" bioprosthesis in patients with acquired aortic or mitral valve diseases.
- Trial name
- Uniline (NCT06025149)
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- Closed Joint-Stock Company NeoCor
Hypertrophic Cardiomyopathy (HCM)
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- REDWOOD-HCM (NCT04219826)
- Testing
- CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg)
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 96 people
- Sponsor
- Cytokinetics
Hypertrophic Cardiomyopathy
Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by hypertrophy of the left ventricular myocardium and is most often caused by mutations in sarcomere genes.
- Trial name
- NCT04402268
- Testing
- Cardioverter-defibrillator
- Where
- Poland
- Volunteers
- 252 people
- Sponsor
- Poznan University of Medical Sciences
Aortic Valve Stenosis
Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)
Transcatheter Aortic Valve Implantation (TAVI) is now the method of choice to treat aortic stenosis in old and frail patients. Antiplatelet therapy must be associated for the procedure and during few weeks after implantation in…
- Trial name
- TICTAVI (NCT02817789)
- Testing
- Ticagrelor alone, Combination lysine acetylsalicylate - clopidogrel
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Aortic Stenosis, Severe
China S3 PMS: SAPIEN 3 China Post Market Registry Study
The objective of this study is to evaluate the long term safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve system in real world setting.
- Trial name
- NCT05168826
- Testing
- SAPIEN 3 Transcatheter Heart Valve
- Where
- 14 sites in China
- Volunteers
- 250 people
- Sponsor
- Edwards Lifesciences
Hypertrophic Cardiomyopathy
Family Studies of Inherited Heart Disease
Hypertrophic cardiomyopathy (HCM) is a genetically inherited heart disease. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle.
- Trial name
- NCT00001225
- Where
- United States
- Volunteers
- 5,880 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Aortic Valve Disease
Safety and Feasibility of TRISKELE in Severe AS
This clinical study is a prospective、single arm and exploratory study, to explore the feasibility and safety of MitrAssist TRISKELE® transcatheter aortic valve system in the treatment of patients with severe aortic stenosis.
- Trial name
- NCT05391191
- Testing
- MitrAssist TRISKELE® transcatheter aortic valve system
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Shanghai Zhongshan Hospital
Acute Kidney Injury
Prevention of Acute Kidney Injury After Transcatheter Aortic Valve Implantation
Randomized controlled, single-center trial randomizing patients with chronic kidney disease and symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI).
- Trial name
- NCT04537325
- Testing
- RenalGuard system
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Aortic Valve Stenosis, Diastolic Dysfunction
Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis
The purpose of this study is to examine the impact of early surgery in patients with asymptomatic severe aortic valve stenosis with signs of subclinical LV dysfunction despite preserved LVEF, with a watchfull waiting approach.
- Trial name
- DANAVR (NCT03972644)
- Testing
- Aortic valve replacement
- Where
- Denmark
- Volunteers
- 1,700 people
- Sponsor
- Odense University Hospital
Hypertrophic Cardiomyopathy, Fibrosis
Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is the most common hereditary heart disease with high mortality. Heart failure is the most common complication (about 50% incidence) in these patients.
- Trial name
- NCT02948998
- Testing
- Spironolactone
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Heart Diseases
Carotid Filtration During Endovascular Aortic Valve Implantation
This study was designed as a First In Man (FIM) trial to evaluate the feasibility and technical capability of the Claret CE Pro System in delivering two embolic filters to the brachiocephalic artery and the left common carotid…
- Trial name
- NCT01484249
- Testing
- CE Pro System
- Volunteers
- 38 people
- Sponsor
- Claret Medical
Long QT Syndrome, Hypertrophic Cardiomyopathy
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
The aim of this study is the identification of familial congenital arrhythmogenic disorders and their clinical follow-up.
- Conditions
- Long QT Syndrome, Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia
- Trial name
- NCT00221832
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Heidelberg University
Williams Syndrome
Fat Distribution and Glucose Metabolism in Williams Syndrome
Williams Syndrome (WS) is a genetic syndrome with features that may include vascular stenoses, neuro-developmental changes, and a variety of endocrine and metabolic abnormalities, including impaired glucose metabolism and…
- Trial name
- NCT01864304
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Aortic Stenosis, Transcatheter Aortic Valve Replacement
EffecTAVI Registry
Aortic stenosis (AS) is the most common valvular heart disease among elderly population, with a increasing prevalence due to population ageing.
- Conditions
- Aortic Stenosis, Transcatheter Aortic Valve Replacement, TAVI
- Trial name
- NCT05235555
- Testing
- Transcatheter heart valve (THV) with CE approval
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Federico II University
Aortic Stenosis
Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
The objective of this study is to evaluate the safety and effectiveness of the Lotus™ Valve System and LOTUS Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with calcific, severe…
- Trial name
- REPRISE III (NCT02202434)
- Testing
- Lotus Valve System, CoreValve/Evolut R Transcatheter Aortic Valve Replacement System, LOTUS Edge Valve System
- Where
- 58 sites in United States, Australia and 4 more
- Volunteers
- 1,425 people
- Sponsor
- Boston Scientific Corporation
Hypertrophic Obstructive Cardiomyopathy
SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy
Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited myocardial disease which leads to the muscle in the wall of the heart growing and thickening to the point that it blocks blood flow exiting the heart with increasing…
- Trial name
- SELECT (NCT04686487)
- Testing
- stereotactic ablative radiotherapy
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Xiangya Hospital of Central South University
Aortic Stenosis
Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis
Whether to intervene in asymptomatic patients with severe aortic stenosis and normal left ventricular ejection fraction remains controversial.
- Trial name
- AVATAR (NCT02436655)
- Testing
- surgical aortic valve replacement
- Where
- 14 sites in Belgium, Croatia and 7 more
- Volunteers
- 157 people
- Sponsor
- Clinical Centre of Serbia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.